IBM will no longer offer, develop, or research facial recognition technology
By Jay Peters,
The Verge
| 06. 08. 2020
IBM’s CEO says we should reevaluate selling the technology to law enforcement
IBM will no longer offer general purpose facial recognition or analysis software, IBM CEO Arvind Krishna said in a letter to Congress today. The company will also no longer develop or research the technology, IBM tells The Verge. Krishna addressed the letter to Sens. Cory Booker (D-NJ) and Kamala Harris (D-CA) and Reps. Karen Bass (D-CA), Hakeem Jeffries (D-NY), and Jerrold Nadler (D-NY).
“IBM firmly opposes and will not condone uses of any [facial recognition] technology, including facial recognition technology offered by other vendors, for mass surveillance, racial profiling, violations of basic human rights and freedoms, or any purpose which is not consistent with our values and Principles of Trust and Transparency,” Krishna said in the letter. “We believe now is the time to begin a national dialogue on whether and how facial recognition technology should be employed by domestic law enforcement agencies.”
Facial recognition software has improved greatly over the last decade thanks to advances in artificial intelligence. At the same time, the technology — because it is often provided by private companies with little regulation...
Related Articles
By Carl Zimmer, The New York Times | 10.20.2026
For the first time, scientists say they have used viruses designed by artificial intelligence to treat a human patient.
Researchers announced on Tuesday that they had administered the virus, known as a phage, to a patient suffering from a deadly...
By Noah Fromson, HealthLab | 10.19.2026
Gene therapy is no longer the future of medicine — it’s reality. Treatments that replace, silence or edit genes are already changing clinical care.
There are more than 6,000 rare genetic disorders but only a fraction currently have treatable targets...
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...